Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?

類似資料

• The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review
  著者:: Wijaya, Indra, 等
  出版事項: (2020)
• The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review
  著者:: Indra Wijaya MD, 等
  出版事項: (2020-10-01)
• Severity of COVID‐19 in end‐stage kidney disease patients on chronic dialysis
  著者:: Andhika, Rizky, 等
  出版事項: (2020)
• A Case Series of HIV-Seropositive Patients and Hypercoagulable State—Is It Difficult to Treat Even with Therapeutic Anticoagulation?
  著者:: Sule, Ashish Anil, 等
  出版事項: (2013)
• Would you use novel oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report
  著者:: Kakadia, Bhavika, 等
  出版事項: (2020)